The outcome to axitinib or everolimus after sunitinib in metastatic renal cell carcinoma
| Autor: | Roberto Sabbatini, Luca Galli, Cristian Lolli, Ugo De Giorgi, Ilaria Toscani, Sebastiano Buti, Giampaolo Tortora, Chiara Miggiano, Giulia Carlo-Stella, Daniele Santini, Elisabetta Nobili, Riccardo Ricotta, Francesco Atzori, Elisa Biasco, Giuseppe Fornarini, Alessandra Mosca, Cristina Masini, Camillo Porta, Carlo Terrone, Melissa Bersanelli, Alessandro Pastorino, Delia De Lisi, Roberto Iacovelli, Franco Nolè, Paolo Andrea Zucali, Gaetano Facchini, Annalisa Guida, Francesco Massari, Sabrina Rossetti, Maria Cossu Rocca, Mario Scartozzi, Carmine Pinto |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2018 |
| Předmět: |
Oncology
second-line medicine.medical_specialty Cancer Research medicine.drug_class medicine.medical_treatment sunitinib axitinib Antineoplastic Agents Kaplan-Meier Estimate urologic and male genital diseases metastatic renal cell carcinoma Tyrosine-kinase inhibitor Drug Administration Schedule everolimus mammalian target of rapamycin sequence tyrosine kinase inhibitor Pharmacology Pharmacology (medical) 03 medical and health sciences 0302 clinical medicine Renal cell carcinoma Internal medicine medicine Humans In patient 030212 general & internal medicine Progression-free survival Carcinoma Renal Cell Retrospective Studies Everolimus Sunitinib business.industry medicine.disease Nephrectomy Kidney Neoplasms Progression-Free Survival Axitinib 030220 oncology & carcinogenesis business medicine.drug |
| Popis: | We aimed to investigate the different outcomes in patients with metastatic renal cell carcinoma treated with second-line axitinib or everolimus after sunitinib. Patients treated in 16 oncological centres in Italy were included, and those receiving axitinib or everolimus from January 2013 onwards were analysed for outcomes. Descriptive statistical tests were used to highlight differences between groups. The Kaplan-Meier method was used to estimate overall survival (OS) and progression-free survival (PFS). Data on 634 patients with metastatic renal cell carcinoma treated with first-line sunitinib have been obtained. A total of 182 patients received a second-line therapy with everolimus (79 patients, 43%) or axitinib (103 patients, 57%), respectively. The median PFS was 4.6 [95% confidence (CI): 2.6-6.5] months for patients treated with everolimus and 5.5 (95% CI: 4.3-6.7) months for patients treated with axitinib (P=0.7). The median OS was 13.9 (95% CI: 10.4-17.4) months for patients treated with everolimus and 12.0 (95% CI: 7.9-16.2) months for patients treated with axitinib (P=0.3). No differences were found based on length of first-line treatment. Major limitations are the retrospective nature of the study and the lack of a prospective evaluation of the progression. This study reports no significantly differences between everolimus and axitinib in terms of both PFS and OS. Furthermore, the length of first-line treatment cannot be used as such a predictive factor and cannot suggest the use of a molecule compared with another. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|